Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | IOS-1002 |
Trade Name | |
Synonyms | IOS 1002|IOS1002 |
Drug Descriptions |
IOS-1002 is fusion protein comprising a modified version of HLA-B57 fused to IgG4 Fc, which targets the LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1 receptors on immune cells and potentially increases antitumor immune response (PMID: 39199672). |
DrugClasses | LILRB2 Antibody 11 |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
IOS-1002 | IOS-1002 | 0 | 1 |
IOS-1002 + unspecified PD-1 antibody | IOS-1002 unspecified PD-1 antibody | 0 | 1 |